Methotrexate compliance among patients with rheumatoid arthritis: The influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study

Scandinavian Journal of Rheumatology

Volumn 39, Issue 3, 2010, Pages 197-205

  De Thurah, A ^a   Norgaard M ^a   Johansen, Mb ^a   Stengaard Pedersen, K ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIPYRETIC AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CHLOROQUINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FOLIC ACID; HEMOGLOBIN; METHOTREXATE; PARACETAMOL; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; COMORBIDITY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; LIVER DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; ULCER;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICATION ADHERENCE; METHOTREXATE; MIDDLE AGED; PATIENT SELECTION; QUESTIONNAIRES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77951823564     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009740903251318     Document Type: Article

References (47)

1. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006; 333: 15. (Pubitemid 44406838)
2. DiMatteo MR. Variations in patients' adherence to medical recommendations: aquantitative review of 50 years of research. Med Care 2004; 42: 200-9.
3. Sackett DLCompliance in health care. Baltimore, John Hopkins University Press: 1979.
4. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld FC, Dougados M, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies including Therapeutics (ESCISIT). Ann Rheum Dis 2007; 66: 34-45. (Pubitemid 46044858)
5. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 15; 59: 762-84. (Pubitemid 351847559)
6. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum 2006; 54: 1401-9.
7. Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rodevand E, Nossent JC. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway. Scand J Rheumatol 2009; 19: 1-6.
8. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39: 975-81.
9. Wluka A, Buchbinder R, Mylvaganam A, Hall S, Harkness A, Lewis D, et al. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice. J Rheumatol 2000; 27: 1864-71. (Pubitemid 30670479)
10. Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000; 27: 1139-47. (Pubitemid 30262496)
11. Hoekstra M, van de Laar MA, Bernelot Moens HJ, Kruijsen MW, Haagsma CJ. Longterm observational study of methotrexate use in a Dutch cohort of 1022 patients with rheumatoid arthritis. J Rheumatol 2003; 30: 2325-9. (Pubitemid 37413888)
12. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-16.
13. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am J Manag Care 2003; 9 (6 Suppl) : S136-43. (Pubitemid 37345201)
14. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF Jr, Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. Med Care 2007; 45 (10 Supl 2) : S66-76.
15. Harrold LR, Andrade SE. Medication adherence of patients with selected rheumatic conditions: a systematic review of the literature. Semin Arthritis Rheum; 38: 396-402.
16. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol 2003; 30: 44-54. (Pubitemid 36077771)
17. Ortendahl M, Holmes T, Schettler JD, Fries JF. The methotrexate therapeutic response in rheumatoid arthritis. J Rheumatol 2002; 29: 2084-91.
18. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43: 22-9. (Pubitemid 30368209)
19. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437-43. (Pubitemid 351466455)
20. Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int 2009; 29: 411-5.
21. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8. (Pubitemid 29299976)
22. Sorensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer 2005; 14; 92: 594-6. (Pubitemid 40395544)
23. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 2003; 2; 88: 1687-92. (Pubitemid 36760410)
24. Guidelines for ATC classification and DDD assignment, 5th edn. Oslo, Norway: World Health Organization, 2002.
25. Introduction to drug utilization research. Oslo, Norway: World Health Organization, 2003.
26. Hetland ML, Unkerskov J, Ravn T, Friis M, Tarp U, Andersen LS, et al. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish database (DANBIO). Scand J Rheumatol 2005; 34: 40-4. (Pubitemid 40445057)
27. Christiansen JU, Maruard CD, Nielsen HC. LABKA. A real-time computer system for the clinical laboratory. Scand J Clin Lab Invest Suppl 1989; 194: 57-61. (Pubitemid 19181619)
28. Kushner I. C-reactive protein in rheumatology. Arthritis Rheum 1991; 34: 1065-8.
29. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K. Associations between acute phase reactant levels and disease activity score (DAS28) in patients with rheumatoid arthritis. Ann Clin Lab Sci 2004; 34: 423-6. (Pubitemid 40040964)
30. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Initial noncompliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiol Drug Saf 2006; 15: 587-93.
31. Bernatsky S, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. Drugs Aging 2008; 25: 879-84.
32. Bring JHow to standardize regression coefficients. Am Stat 1994; 48: 209-11.
33. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. J Clin Epidemiol 2006; 15: 11-17. (Pubitemid 41797470)
34. Papadopoulos NG, Alamanos Y, Papadopoulos IA, Tsifetaki N, Voulgari PV, Drosos AA. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study. J Rheumatol 2002; 29: 261-6. (Pubitemid 34118770)
35. Ideguchi H, Ohno S, Ishigatsubo Y. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis. J Clin Rheumatol 2007; 13: 73-8. (Pubitemid 46597669)
36. Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64: 207-11. (Pubitemid 40193613)
37. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15: 565-74; discussion 575-7. (Pubitemid 44336271)
38. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmacother 2006; 40: 1280-8.
39. Yazici Y, Erkan D, Harrison MJ, Nikolov NP, Paget SA. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol 2005; 40: 517-20. (Pubitemid 41447624)
40. Aletaha D, Kapral T, Smolen JS. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 2003; 62: 482-6. (Pubitemid 36469745)
41. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39: 723-31.
42. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
43. Owen SG, Friesen WT, Roberts MS, Flux W. Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 1985; 24: 313-20. (Pubitemid 16250723)
44. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 2008; 4: 269-86.
45. DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care 2007; 45: 521-8.
46. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the 'anchor drug' for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: S179-85. (Pubitemid 37265610)
47. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007; 66: iii56-60.